GH Research PLC (GHRS)
NASDAQ: GHRS · Real-Time Price · USD
6.85
-0.54 (-7.31%)
At close: Dec 20, 2024, 4:00 PM
7.19
+0.34 (4.96%)
After-hours: Dec 20, 2024, 7:37 PM EST
GH Research Employees
GH Research had 49 employees as of December 31, 2023. The number of employees increased by 17 or 53.13% compared to the previous year.
Employees
49
Change (1Y)
17
Growth (1Y)
53.13%
Revenue / Employee
n/a
Profits / Employee
-$845,531
Market Cap
356.39M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 49 | 17 | 53.13% |
| Dec 31, 2022 | 32 | 18 | 128.57% |
| Dec 31, 2021 | 14 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Enhabit | 10,800 |
| ZimVie | 2,600 |
| Quanterix | 441 |
| Allogene Therapeutics | 233 |
| Personalis | 225 |
| Alpha Teknova | 211 |
| Akebia Therapeutics | 167 |
| Nano-X Imaging | 164 |
GHRS News
- 5 weeks ago - GH Research Reports Third Quarter 2024 Financial Results and Provides Business Updates - GlobeNewsWire
- 3 months ago - GH Research Reports Second Quarter 2024 Financial Results and Provides Business Updates - GlobeNewsWire
- 3 months ago - GH Research Announces Appointment of Dr. Velichka “Villy” Valcheva to Chief Executive Officer - GlobeNewsWire
- 8 months ago - GH Research Reports First Quarter 2024 Financial Results and Provides Business Updates - GlobeNewsWire
- 10 months ago - GH Research Reports Full Year 2023 Financial Results and Provides Business Updates - GlobeNewsWire
- 1 year ago - GH Research Announces Grant of European Patent Covering all Mebufotenin (5-MeO-DMT) and Mebufotenin Salt Products For Use in the Treatment of Major Depressive Disorder and Treatment-Resistant Depression - GlobeNewsWire
- 1 year ago - GH Research Reports Third Quarter Financial Results and Provides Business Updates - GlobeNewsWire
- 1 year ago - GH Research Provides Updates and Guidance on its Clinical Development Program for GH001 in Treatment-Resistant Depression - GlobeNewsWire